Nano Pro-Drug

~ Design & Efficacy of Nano Carrier-free DDS ~

Department of Intellectual Property Management

KEY INVENTION

A novel Drug Delivery System (DDS) selectively to deliver drugs to the target cells (tissues) has been developed with no use of Nano Carriers.

Drug Administration

[Challenges]
Drug to spread in the body due to the molecular size
⇒ Low efficacy or side effects would be concerned about.

Nano Carrier DDS

[Challenges]
- Low Cell Permeability
- Low Drug-support Rate (< 10%)
- Side effects by Nano Carrier would be concerned about.

Nano Pro-Drug (Nano Carrier-free DDS)

[Characteristics]
A nano drug consisting of only APIs
⇒ The drug-support rate is high, and no side effect by nano carrier would be concerned about.



SUMMARY of INVENTION



- Topoisomerase Inhibitor
- Low Water Solubility (Water Solubility < 5 ppm)
- Irinotecan (pro-drug) is used for cancer treatment.



H. Kasai *et al.*, *Jpn. J. Appl. Phys.* **1992**

[Examples of SN-38 Dimers]





COMPARISON with and ADVANTAGE over CURRENT TECHNOLOGY

[Current Technology]



Irinotecan
- Pro-Drug of SN-38
- Used for cancer treatment

cf. Comparison of SN-38 with Irinotecan

	Water Solubility	Efficacy
SN-38	×	◎
Irinotecan	○	△

The water solubility of Irinotecan is higher than that of SN-38.

[Efficacy Comparison of this technology with the current technology]

a. Administration Concentration vs. Apoptosis



SN-38 dimers induce apoptosis at a higher late than Irinotecan.

b. Antitumor Activity by Topical Treatment



SN-38 dimer shows a higher antitumor activity than Irinotecan.

APPLICATION expected

◎ Development of the low-molecule drugs such as antitumor agents using nano pro-drug as an alternative of the current DDS technologies

◎ Development of the novel DDS technology without nano carrier

Representative Inventor: Hitoshi Kasai (Professor, Tohoku University)
Co-Inventor: Yoshitaka Koseki (Assistant Professor, Tohoku University), et al.

Licensable Patent

Title of Invention: Pharmaceutical Multimeric Particles, and Manufacturing Method for Same
International Publication No.: WO2011155501

Contact: IP Management & Licensing Group,
Department of Intellectual Property Management, JST
TEL) +81-3-5214-8486 email) license@jst.go.jp
URL) www.jst.go.jp/chizai/